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Objective: To describe recovery of adrenal insufficiency in asthmatic children treated with 
inhaled corticosteroids (ICS) and cortisol replacement therapy.
Design: Retrospective, observational study.
Patients: A total of 113 patients, 74 male; age 10.4 (3.3–16.5) years; beclomethasone- equivalent 
ICS dose, 800 µg, (100–1,000), tested by low dose short Synacthen (tetracosactide) test (LDSST), 
were studied. Test results were classified by basal and peak cortisol concentration: “normal” 
(basal >100 nmol/L, peak >500 nmol/L), “suboptimal” (basal >100 nmol/L, peak 350–499 
nmol/L), “abnormal” (basal <100 nmol/L and/or peak <350 nmol/L). Patients with suboptimal 
results received hydrocortisone during periods of stress only, and those with abnormal responses 
received daily hydrocortisone, increased during periods of stress. A total of 73 patients (68%) 
had ≥2 LDSSTs over 2.2 years (0.2–7.7).
Measurements: Change in cortisol response to repeat LDSST (movement between diagnostic 
groups, difference in basal and peak cortisol >15% [2× the inter-assay coefficient of variation]), 
change in BMI and height standard deviation score (SDS).
Results: Baseline test results were abnormal in 17 patients (15%) and all of them had repeat 
tests. In 13 patients (76%), test results improved (normal in six, suboptimal in seven) and four 
(24%) remained abnormal. Baseline tests results were suboptimal in 54 patients (48%), of whom 
50 (93%) were retested. Repeat tests were normal in 36 patients (72%), remained suboptimal in 
11 (22%), and were abnormal in three (6%). Baseline tests results were normal in 42 patients, 
of whom six patients (14%) were retested. Results remained normal in three (50%), were sub-
optimal in two (33%), and abnormal in one (17%). Basal and peak cortisol levels increased by 
>15% in 33/73 (45%) and 42/73 (57%) patients, respectively, and decreased by >15% in 14/73 
(19%) and 7/73 (10%), respectively. There was no significant change in height or BMI SDS.
Conclusion: Recovery of adrenal function is common and occurs during continued ICS and 
cortisol replacement therapy.
Keywords: HPA axis recovery, adrenal suppression, childhood asthma, inhaled steroids (ICS), 
LDSST
Introduction
Asthma is the commonest chronic disorder of childhood, affecting 14% of children 
worldwide, with wide geographical variation in prevalence.1 The use of inhaled corti-
costeroids (ICS) is recommended from step two of the British Thoracic Society (BTS) 
guidelines for the management of asthma.2 The side-effect profile of ICS therapy has 
been reported widely.3–9 Hypothalamo–pituitary–adrenal (HPA) axis suppression is 
reported in 20%–40% of unselected cohorts of children,3–7 including those treated 
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with beclomethasone equivalent 200 µg/day,8 the starting 
dose recommended by BTS.2 Adrenal crisis and death has 
been reported in rare cases.4,7,9,10
The optimal surveillance and management protocols for 
children at risk of adrenal insufficiency during ICS therapy 
is a matter of ongoing discussion, and the need for further 
research was highlighted in a recent review article from the 
Pediatric Endocrine Society Drugs and Therapeutics Com-
mittee.11 To date, there are very few data reporting recovery 
of HPA axis suppression during ICS therapy.12–16 Patel et al 
described the recovery of adrenal function in a small case 
series of patients who presented acutely with adrenal crisis or 
insidiously with poor growth.7 A case report showed complete 
recovery of adrenal insufficiency and catch-up growth in a 
teenager following cessation of ICS therapy,8 and recovery 
of the HPA axis has also been reported in a small group of 
children when oral prednisolone was stopped or changed 
to ICS.17
We have reported adrenal function in children with 
asthma, treated with ICS, tested with a simplified low dose 
short tetracosactide test (LDSST) protocol previously,18 and 
a suggested management plan for children with secondary 
adrenal insufficiency. In this protocol, we have stratified 
hydrocortisone replacement therapy according to baseline 
and peak cortisol responses, because the clinical significance 
of modestly impaired results is uncertain.19 In doing so, we 
aimed to avoid overtreatment in children at lowest risk of 
adrenal crisis while ensuring treatment of children at greatest 
risk. Test results in which the basal cortisol concentration is 
≥100 nmol/L and peak cortisol concentration is ≥500 nmol/L 
are classified as “normal”. Peak cortisol concentrations of 
350–499 and <350 nmol/L are classified as “suboptimal” and 
“abnormal” responses, respectively. Basal cortisol concentra-
tions <100 nmol/L, when the test is performed before 10.00, 
are also classified as “abnormal”. Patients with a suboptimal 
response are treated with hydrocortisone (20 mg/m2/d) dur-
ing periods of acute illness only. Patients with an abnormal 
response are treated with daily hydrocortisone at a dose of 
5–7.5 mg/m2/d, and 20 mg/m2/d during acute illness.
The aim of this retrospective study was to describe 
recovery of adrenal function to “normal” in children with 
“suboptimal” or “abnormal” responses to the LDSST. We 
examined change in ICS doses during the observation period, 
to determine whether a reduction in steroid exposure was 
required for recovery of the HPA axis. Furthermore, we exam-
ined change in body mass index (BMI) and height standard 
deviation score (SDS) as evidence of glucocorticoid excess 
in children treated with hydrocortisone.
Methods
Patients
This retrospective study examined cortisol responses to 
the LDSST performed between 2008 and 2016 in children 
treated with ICS for asthma. The cohort comprised patients 
identified as being at increased risk of HPA axis suppression 
that is those patients receiving high doses of ICS doses, and 
those with symptoms suggestive of adrenal insufficiency. 
These patients were treated in a tertiary-level service in 
a specialist children’s hospital. Moreover, we included an 
unselected group of pediatric patients with asthma, treated 
in secondary and tertiary-care centers, who had participated 
in a previous research study.18
Corticosteroid doses were recorded at the time of each 
LDSST, and expressed in microgram per day of beclometha-
sone dipropionate equivalent.16 The following dose equiva-
lents were used: 1:1 for clenil modulite and budesonide; 2:1 
for fluticasone, mometasone; and 1:4 for prednisolone.2,17
Patients treated with oral steroids continuously or on 
alternate days are discussed separately in view of the small 
numbers (n=6) and very high total steroid doses. These 
patients were tested on a day on which prednisolone was 
due, but before the dose was given, to allow the HPA axis to 
escape from prednisolone suppression.
lDssT protocol
Adrenal function was assessed using the simplified LDSST 
protocol as previously described.4,18 Briefly, blood is collected 
(0 min) upon peripheral venous cannula insertion, tetraco-
sactide (500 ng/1.73 m2) is administered as an intravenous 
bolus, and three further blood samples are collected at 15, 
25, and 35 minutes following tetracosactide administration.
All tests were undertaken in the morning.
cortisol assays
An automated immunoassay analyzer (IMMULITE 2000 
XPi, Siemens Health care, Camberley, UK) was used for 
measurement of serum cortisol. The intra-assay coefficient 
of variation is <5% and inter-assay coefficient of variation 
is <7.7%.
Data were collected from computerized hospital data 
system. The study protocol was reviewed and approved by 
the Clinical Research Business Unit at Alder Hey Children’s 
Hospital, Liverpool, UK who deemed that, as anonymized 
data were used in this retrospective, observational study, 
approval and informed consent from a Research Ethics Com-
mittee was not required. However, a formal ethical approval 
from the Liverpool local research ethics committee (Liver-
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pool Children’s Research Ethics Committee) was obtained 
for the unselected group of asthma patients who were part of 
previous research study (Reference-07/H100/63).18
Data analysis
In patients with two or more LDSSTs, we analyzed change 
between the first baseline test and the most recent test. We 
described movement between diagnostic groups, given the 
clinical relevance of this outcome. Moreover, we described the 
number of patients in whom basal and peak cortisol changed by 
>15% – twice the inter-assay coefficient of variation. Further-
more, we assessed change in height and BMI SDS as evidence 
of an adverse effect of hydrocortisone replacement therapy.
Statistical calculations were performed using SPSS (IBM 
Corp. Released 2013. IBM SPSS Statistics for Macintosh, 
Version 22.0. Armonk, NY: IBM Corp). A p-value <0.05 
was considered significant. Statistical calculations including 
subgroup analysis were carried out to assess the relation-
ship between basal and peak cortisol concentrations, the 
outcomes of LDSSTs and ICS doses. Wilcoxon signed-rank 
test was used to assess the differences between the variables 
in subgroup analyses.
Results
Patient demographics
Data were available for 113 patients, of whom 74 (65%) were 
male. Seventy-three (65%) were selected on the basis of high 
levels of ICS exposure or symptoms of adrenal insufficiency. 
Forty patients (35%) were from an unselected cohort of 
pediatric patients with asthma who had participated in our 
previous study.18
The median (range) age at the time of the first LDSST 
was 10.4 (3.3–16.5) years, and duration of follow-up was 1.3 
(0–7.7) years. Seventy-three patients (68%) had more than 
one LDSST, with the median number of tests per patient 
being 2.7 (2–7).
ics doses
The median (range) ICS dose at the time of the first LDSST was 
800 (100–1,000) µg and, at the final LDSST, 500 (100–2,000) 
µg. Changes in ICS dose for individual patients are shown in 
Table S1. Although the median steroid dose at the final follow-
up point was less than the initial dose, this failed to reach 
statistical significance. Median ICS dose was lower in boys 
than girls: ICS dose 500 (100–1,000) µg and 450 (100–1,200) 
µg at baseline and final LDSST, respectively, in boys, versus 
800 (200–1,000) µg and 800 (200–2,000) µg in girls (p=0.048).
Patient characteristics are described in Table 1.
lDssT outcomes
Baseline test
Seventeen patients (15%; 12 male; median age [range] 8.6 
[3.3–16.5] years) had an abnormal result, 54 patients (48%; 
37 male; 10.9 [4.7–15.6] years) had a suboptimal result, and 
42 (37%; 25 male; 10.4 [3.8–14.8] years) patients had a nor-
mal result on their first test. Among those with an abnormal 
result, basal cortisol levels were <100 nmol/L in nine patients. 
Characteristics of patients in each group, at baseline and at 
the time of the most recent LDSST, are given in Table 2.
Outcomes of follow-up lDssT
1. Patients with an initial abnormal result
All 17 (100%) patients with an abnormal result on the first 
test underwent follow-up LDSST. Cortisol response on repeat 
testing was normal in six patients (35%), suboptimal in seven 
patients (41%), and in remained abnormal in four patients 
(24%). In the nine patients in whom basal cortisol was <100 
nmol/L on the first test, repeat test results were normal in 
three, suboptimal in five, and remained abnormal in one.
2. Patients with an initial suboptimal result
A total of 50/54 (93%) patients underwent a further LDSST, 
of which 36 (72%) were normal. Eleven (22%) patients 
Table 1 Patient characteristics
Patient characteristics All patients One LDSST only ≥2 LDSST
Total/male (%) 113/74 (65%) 40/24 (60%) 73/50 (68%)
Median (range) age (years) 10.4 (3.3–16.5) 9.8 (3.8–14.8) 10.8 (3.3–15.6)
Median (range) follow-up period (years) 1.3 (0–7.7) nA 2.2 (0.2–7.7)
Total number of lDssTs 238 40 198
Average number of tests/patient 2.1 (1–7) 1.0 2.7 (2–7)
ics-start (µg/day) 800 (100–1,000) 500 (100–1,000) 800 (2001,000)
ICS-final (µg/day) 500 (100–2,000) 750 (100–2,000)
ht sDs – start
−0.3 (−3.3 to +2.8) −0.4 (−3.3 to +2.8) −0.2 (−3.0 to +2.8)
Ht SDS – final
−0.3 (−2.4 to +2.9) −0.3 (−2.4 to +2.9)
BMi sDs – start +0.7 (−2.0 to +3.6) +1.0 (−1.8 to +3.6) +0.6 (−2.0 to +3.2)
BMI SDS – final +0.7 (−1.7 to +3.1) +0.7 (−1.7 to +3.1)
Abbreviations: lDssT, low dose short tetracosactide test; ics, inhaled corticosteroid; ht, height; sDs, standard deviation score; BMi, body mass index.
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 continued to have a suboptimal result and three (6%) patients 
had an abnormal result.
We were unable to identify repeat LDSST results for four 
patients in whom the cortisol response was suboptimal in the 
first LDSST. Among those, two patients were transferred to adult 
services and two moved out to another region. At the time of the 
first LDSST, the median age of these patients was 9.9 (5.8–14) 
years, 2/4 were male, and ICS dose was 750 (400–1,000) µg/
day. The median baseline cortisol on the first LDSST was 
222 (174–301) nmol/L and peak cortisol was 454 (417–499) 
nmol/L. All patients except one (female, 5.8 years of age at first 
LDSST, ICS dose 400 µg/day, moved to a different region) were 
confirmed to be on appropriate steroid replacement therapy.
3. Patients with an initial normal result
In total, 6/42 (14%) patients underwent a further LDSST 
because of ongoing clinical concern about the possibility 
of HPA axis suppression. Of these six patients, two had a 
suboptimal response, and one had an abnormal response.
Movement of patients between diagnostic groups is given 
in Figure 1.
change in basal and peak cortisol concentrations
For all patients that underwent a repeat LDSST, mean±1 SD 
basal cortisol concentration increased by 38±139 nmol/L – 
from 192±81 to 244±113 nmol/L. In 33/73 (45%) showed 
>15% increase, 14/73 (19%) showed >15% decrease of basal 
cortisol response from the baseline, and 16/73 (22%) showed 
less than 15% change in either response. In 10 patients (14%) 
in whom repeat LDSST data were obtained from clinic cor-
respondence, the baseline result was documented as being 
>100 nmol/L, but no absolute value was given.
Peak cortisol concentration increased by 86±130 nmol/L 
– from 423±100 to 509±129 nmol/L. A total of 42/73 (57%) 
showed >15% increase, 7/73 (10%) showed >15% decrease 
of peak cortisol response from the baseline, and 24/73 (33%) 
showed less than 15% change either way (Figure S1).
change in height and BMi sDs
In the suboptimal group, median height and BMI SDS did 
not change between the first and last LDSST. In the abnormal 
group, the median height SDS fell from −0.2 to −0.7, imply-
ing slow growth, and BMI SDS fell from +1.2 to +0.8. These 
changes were not statistically significant.
Oral steroid therapy
Patients treated with oral steroid therapy are indicated by * 
in Figure 1.
The median age of these six patients was 8.8 years (range 
5.8–12.2) and follow-up period was 7.0 years (4.3–7.9). The 
oral prednisolone dose range was 7.5–10 mg on alternate days 
(0.12–0.29 mg/kg/d, median 0.2 mg/kg/d). The median total 
steroid dose (both inhaled and oral) at the start was 20,900 
µg/day (range 16,000–21,000) and, at the final follow-up, 
LDSST was 20,900 µg/day (range 11,000–21,500).
Among these six patients, three underwent repeat testing. 
Two patients had suboptimal results on the first LDSST, of 
which one remained suboptimal (asthma treatment: pred-
nisolone 5 mg on alternate days and ICS 1,000 µg/day) and 
one became abnormal (asthma treatment: 10 mg of oral pred-
nisolone on alternate days, i.e., 0.1 mg/kg/day and ICS 1,500 
µg/day). One patient, treated with 10 mg oral prednisolone 
on alternate days, that is, 0.05 mg/kg/day and 1,000 µg/day 
of ICS, had an abnormal LDSST result, which returned to 
Table 2 Patients characteristics classified according to cortisol concentrations on the first LDSST
Group characteristics Normal (≥500 nmol/L) Suboptimal (350–499 nmol/L) Abnormal (<350 nmol/L)
number (% of total) 42 (37%) 54 (48%) 17 (15%)
sex (male:female) 25:17 37:17 12:5
Age at first test (years) 10.4 (3.8–14.8) 10.9 (4.7–15.6) 8.6 (3.3–16.5)
Age at final test (years) 10.8 (3.8–14.8) 14.0 (5.8–18.4) 12.4 (7.4–18.1)
F/U period (years) 0 (0–4.5) 2.0 (0–7.7) 1.6 (0.2–7.2)
Total lDssTs 51 140 47
Average tests/person 1.2 2.6 2.8
ICS dose at first LDSST (µg/day) 500 (100–1,000) 800 (200–1,000) 800 (200–1,000)
ICS dose at final LDSST (µg/day) 500 (100–1,000) 750 (100–2,000) 650 (200–1,200)
ht sDs baseline
−0.4 (−3.3 to +2.8) −0.3 (−3.0 to +2.8) −0.2 (−1.7 to +2.5)
Ht SDS final
−0.4 (−1.0 to +0.7) −0.3 (−2.4 to +1.5) −0.7 (−1.9 to +2.9)
BMi sDs baseline +0.9 (−1.8 to +3.6) +0.5 (−2.0 to +3.2) +1.2 (0 to +3.1)
BMI SDS final +0.6 (−0.2 to +3.0) +0.7 (−1.3 to +2.8) +0.8 (−1.7 to +3.1)
Abbreviations: F/U, follow-up; lDssT, low dose short tetracosactide test; ics, inhaled corticosteroid; ht, height; BMi, body mass index; sDs, standard deviation score.
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normal on repeat testing. The remaining three patients had 
normal results and were not tested further.
Discussion
Biochemical evidence of adrenal suppression is common in 
children treated with ICS, and symptomatic adrenal insuffi-
ciency – including death from adrenal crisis – is described.4–7 
However, much less is known about the recovery of HPA 
axis function during ICS therapy. To our knowledge, this is 
the largest cohort of patients described to date. These data 
are important; they should reassure clinicians and families 
that recovery of the HPA axis occurs in most patients and 
that treatment with hydrocortisone, in modest doses, is not 
associated with further deterioration in adrenal function.
There was no significant difference in ICS dose between 
those in whom the LDSST was normal and those with 
 suboptimal and abnormal responses. This observation is 
consistent with our previous data from unselected cohorts of 
patients,18,20 and is surprising. This may reflect variable con-
cordance with ICS treatment, differences in drug deposition 
in the lung and oral cavity, and variable drug absorption. It is 
important to note that we recorded only steroid therapy pre-
scribed for asthma. Patients with other atopic conditions are 
likely to have been treated with intranasal or dermal steroids, 
which may also influence HPA axis activity. Finally, genetic 
determinants of glucocorticoid sensitivity and adverse effects 
have been reported widely,21,22 and it is likely that genetic 
factors also influence individual susceptibility to HPA axis 
suppression during ICS therapy as well as HPA axis recovery.
Seventy-three percent of patients with a suboptimal 
or an abnormal result to the first LDSST showed at least 
partial recovery of the HPA axis, including eight of the nine 
Figure 1 Movement of patients between diagnostic groups according to cortisol response to the final LDSST. Beclomethasone equivalent doses of ICS (μg/day) are shown 
at each time point: Median (range).
Note: number of asterisk marks (*) indicates the total number of patients on oral steroids in addition to ics and their movements during follow-up.
Abbreviations: lDssT, low dose short tetracosactide test; ics, inhaled corticosteroid.
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patients with baseline cortisol concentrations <100 nmol/L. 
Reasons for this high rate of recovery during ongoing ICS 
and hydrocortisone treatment are unclear. Impaired cortisol 
responses to the LDSST have been described in a small 
cohort of children with asthma before the introduction of 
ICS, with recovery during ICS treatment,23 and there is some 
evidence that adrenal function is impaired in children with 
longstanding atopic conditions.24 It is possible that mild 
impairments of adrenal function are a feature of atopy, with 
a natural history of recovery over time, although it seems 
unlikely that ICS plays no role in this process. Following a 
diagnosis of adrenal insufficiency, parents and patients attend 
an education appointment with an endocrine nursing special-
ist, in which they learn about the risk and clinical features 
of adrenal crisis as well as how to adjust hydrocortisone 
doses during periods of stress and, in patients with abnormal 
results, how to administer intramuscular hydrocortisone in 
the unconscious child. We speculate that parents who feel 
their child’s asthma is well treated may reduce their doses of 
ICS in response to this information, and this may facilitate 
recovery of adrenal function.
In this study, 65% of patients were tested because they 
were felt to be at increased risk of HPA axis suppression 
because of their steroid exposure or because they complained 
of symptoms of adrenal insufficiency including lethargy, 
headache, abdominal pain, poor concentration, nausea, etc. 
The remaining 35% of patients were from a large, unselected 
cohort of patients, who were studied to determine the clini-
cal utility of salivary biomarkers as screening tests for the 
identification of children with HPA axis suppression.18 In our 
previous study of unselected patients, LDSST results were 
abnormal in 4.5% and suboptimal in 37.5%, compared to 
15% and 48% in the selected cohort of patients reported in 
this article, suggesting use of steroid exposure and clinical 
features of adrenal insufficiency as a means of identifying 
those that should be tested is helpful.
In our center, we aim to retest patients with impaired or 
abnormal results every 6 months. However, the clinical sta-
tus of the patient often determines the time of repeat test. In 
patients with “impaired” results who develop clinical features 
of adrenal insufficiency, LDSSTs will be conducted at an ear-
lier stage, whereas LDSSTs are deferred in children in whom 
asthma symptoms deteriorate and increased doses of steroids 
are required. Standardizing diagnostic protocols, within these 
limitations, will be important in future, prospective work.
Patients with abnormal results were treated with low doses 
of hydrocortisone (5–7.5 mg/m2/day, normal replacement 
doses being 8 mg/m2/day),25 based on an assumption that 
there must be some systemic absorption of ICS to induce 
HPA axis suppression and a desire to maintain children in 
good health while minimizing an increase to their steroid 
burden. We observed a slowing of growth in those treated 
with daily hydrocortisone, but no gain in BMI SDS. A recent 
Cochrane review concluded that low- or medium-dose ICS 
results in a drop of longitudinal height by 0.48 cm/year and 
the adverse effect on the growth is likely to depend on the 
molecule of ICS that is used.26 This may account, in part, for 
some of the reduction in height SDS observed among our 
patients. Moreover, we observed a reduction in BMI SDS, 
which would be unexpected if the doses of hydrocortisone 
used in this treatment protocol were sufficient to cause a 
deceleration in growth.
Several tests are used for the assessment of the HPA 
axis. The short tetracosactide test is the most convenient 
and safest method of assessment, but has some limitations.19 
The standard-dose short tetracosactide test (SDSST) uses a 
supra-physiological dose of tetracosactide (250 µg) whereas 
the LDSST uses a more physiological dose (500 ng/1.73 m2) 
and produces similar peak cortisol response as the SDSST in 
healthy patients.16 Meta-analyses in both adult and pediatric 
populations have consistently found the LDSST to be more 
sensitive, and the SDSST to be more specific.12–16
Previously, a study by Gupta et al on the test–retest repeat-
ability of the LDSST in 18 children with asthma reported only 
fair to good agreement when two LDSSTs were conducted 
with an interval of 1 month.27 However, it should be noted 
that in that study, samples were only collected at 20 and 
30 minutes. The simplified LDSST used in our study was 
developed from raw data from LDSSTs undertaken in 400 
children with asthma, sampled more intensively.4 Sampling 
at 15, 25, and 35 minutes enabled all children to be classified 
as having normal, impaired, or abnormal responses, whereas 
20 and 30 minutes did not. This difference in test protocol 
may account, in part, for the poor test–retest reproducibility 
reported previously.4
The definition of a “normal” and “abnormal’ response 
to the LDSST is based on studies conducted in healthy 
children and those known to be at high risk of adrenal 
impairment.19 A normal response is generally considered to 
have a peak cortisol >500 nmol/L, or an increment in cor-
tisol of >200 nmol/L.19 However, there is a clear disparity 
in the high prevalence of biochemical abnormalities of the 
HPA axis and very low prevalence of symptoms of chronic 
adrenal insufficiency and adrenal crisis during ICS therapy 
for asthma. In the development of the protocol used for the 
management of patients in this study and those published 
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previously, we  carefully reviewed case reports and case series 
of adrenal crisis during ICS therapy in childhood, obtaining 
individual patient data from corresponding authors wherever 
possible.7,9,10,28–31 In these studies, assessments of adrenal 
reserve included the LDSST, SDSST, and/or glucagon tests. 
All patients who were tested in the non-acute setting had 
peak cortisol values <350 nmol/L on provocation testing, and 
generally <200 nmol/L. We, therefore, stratified our approach 
to adrenal replacement therapy, where only those with basal 
cortisol <100 nmol/L, and/or low peak cortisol concentrations 
(<350 nmol/L) should receive daily treatment, with those with 
peak cortisol concentrations between 350 and 499 nmol/L 
administered hydrocortisone only during periods of stress.
Limitations
We were unable to identity follow-up LDSST data for four 
patients with an initial suboptimal result, and the absolute 
values of the baseline cortisol concentration was not available 
for 10 patients. In a relatively small cohort of patients, these 
missing data may significantly influence the rates of adrenal 
recovery presented in this article.
We have no measure of concordance with either ICS 
or hydrocortisone, and it is important that relationships 
between doses of these medications and LDSST results are 
interpreted cautiously. Furthermore, we have not recorded 
any concomitant steroid medication use, such as intranasal 
or dermal steroids.
We did not measure clinical features of adrenal insuffi-
ciency objectively before testing, or following the introduc-
tion of hydrocortisone replacement therapy. For this reason, 
we are unable contribute to the discussion with regard to the 
clinical significance of modestly impaired cortisol responses 
to the LDSST. Symptoms of adrenal insufficiency are vague, 
are difficult to quantify, and can be attributed to many differ-
ent causes. In order for this issue to be resolved, robust tools 
for the measurement and monitoring of clinical features of 
adrenal insufficiency in children and young people over time 
need to be developed. Such a tool would enable this important 
question to be addressed in a rigorous clinical study.
Conclusion
Suppression of the HPA axis is common in children using 
ICS. Although recovery of axis occurs in the majority of 
patients on ICS, the exact pathophysiology of HPA axis 
suppression in some and relative protection in others needs 
careful consideration. Robust clinical studies are required 
to determine which children should be tested and treated, to 
develop clinical tools to identify and monitor children with 
adrenal insufficiency, and to determine the optimal diagnostic 
and treatment protocols.
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Supplementary materials
Table S1 ics doses of suboptimal and abnormal group
ICS at first and final LDSST tests: median (range) in microgram
Suboptimal group: ICS Abnormal group: ICS
Initial (A) Final (B) A–B Initial (A) Final (B) A–B
500 500 0 500 500 0
400 400 0 1,000 1,000 0
500 400 100 800 400 400
400 200 200 400 400 0
800 800 0 400 400 0
1,000 1,200
−200 1,000 1,000 0
1,000 1,000 0 800 800 0
1,000 1,000 0 1,000  1,000
1,000 400 600 400 400 0
1,000 1,000 0 1,000 800 200
200 200 0 800 800 0
400 400 0 200 200 0
500 1,000
−500 800 1,200 −400
400 400 0 400 400 0
1,000 1,000 0 1,000 1,000 0
400 2,000
−1,600 400 400 0
1,000 800 200 1,000 1,000 0
400 400 0
1,000 1,000 0
300 300 0    
500 500 0    
1,000 1,000 0    
400 400 0    
800 100 700    
1,000 1,200
−200    
800 800 0    
1,000 1,000 0    
1,000 1,000 0    
1,000 1,000 0    
1,000 250 750    
1,000 800 200    
200 100 100    
400 200 200    
1,000 400 600    
1,000 1,000 0    
500 500 0    
500 500 0    
1,000  1,000    
400 400 0    
1,000 1,000 0    
1,000 1,500
−500    
800 2,000
−1,200    
400 800
−400    
800 800 0    
500 500 0    
1,000 1,000 0    
800 1,000
−200    
1,000 1,000 0    
400 400 0    
400 400 0    
500 500 0    
750 750 0    
400 400 0    
400 400 0    
800 (200–1,000) 750 (100–2,000) 0(−1,600–1,000) 800 (200–1,000) 650 (200–1,200) 0 (−400–1,000)
Note:  Median (range) in microgram/day are shown in bold.
Abbreviations: ics, inhaled corticosteroid; lDssT, low-dose short tetracosactide test.
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Figure S1 changes in basal and peak cortisol concentrations.
Changes in
cortisol
concentrtation
(total: 73)
Changes in basal
cortisol
>15% increase
33/73 (45%)
>15% decrease
14/73 (19%)
<15% change (±)
16/73 (22%)
Insufficient data
10/73 (14%)
Changes in peak
cortisol
>15% increase
42/73 (57%)
>15% decrease
7/73 (10%)
<15% change (±)
24/73 (33%)
